Jaakko Helve1,2, Reijo Sund3,4, Martti Arffman4,5, Valma Harjutsalo6,7, Per-Henrik Groop8,2,6,7,9, Carola Grönhagen-Riska8, Patrik Finne8,2. 1. Finnish Registry for Kidney Diseases, Helsinki, Finland jaakko.helve@helsinki.fi. 2. Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 3. Department of Social Research, Centre for Research Methods, University of Helsinki, Helsinki, Finland. 4. Insitute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland. 5. National Institute for Health and Welfare, Helsinki, Finland. 6. Diabetes and Obesity Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland. 7. Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland. 8. Finnish Registry for Kidney Diseases, Helsinki, Finland. 9. Baker IDI Heart & Diabetes Institute, Melbourne, Australia.
Abstract
OBJECTIVE: To investigate how risk of end-stage renal disease (ESRD) among patients with type 1 diabetes has changed over time and further how the risk is affected by age, sex, and time period of diagnosis of diabetes. RESEARCH DESIGN AND METHODS: A cohort including all patients <30 years old diagnosed with type 1 diabetes in Finland in 1965-2011 was followed until start of renal replacement therapy, death, or end of follow-up at the end of 2013. Altogether, 29,906 patients were included. The main outcome was cumulative risk of ESRD, accounting for death as a competing risk. RESULTS: The patients were followed up for a median of 20 years. During 616,403 patient-years, 1,543 ESRD cases and 4,185 deaths were recorded. The cumulative risk of ESRD was 2.2% after 20 years and 7.0% after 30 years from the diabetes diagnosis. The relative risk of ESRD was 0.13 (95% CI 0.08-0.22) among patients diagnosed in 1995-2011 compared with those diagnosed in 1965-1979. Patients <5 years old at the time of diagnosis had the lowest risk of ESRD after diagnosis. With the cumulative risk of ESRD estimated from time of birth, the patients aged 5-9 years at diabetes diagnosis were at highest risk. CONCLUSIONS: The cumulative risk of ESRD has decreased markedly during the past five decades. This highlights the importance of modern treatment of diabetes and diabetic nephropathy.
OBJECTIVE: To investigate how risk of end-stage renal disease (ESRD) among patients with type 1 diabetes has changed over time and further how the risk is affected by age, sex, and time period of diagnosis of diabetes. RESEARCH DESIGN AND METHODS: A cohort including all patients <30 years old diagnosed with type 1 diabetes in Finland in 1965-2011 was followed until start of renal replacement therapy, death, or end of follow-up at the end of 2013. Altogether, 29,906 patients were included. The main outcome was cumulative risk of ESRD, accounting for death as a competing risk. RESULTS: The patients were followed up for a median of 20 years. During 616,403 patient-years, 1,543 ESRD cases and 4,185 deaths were recorded. The cumulative risk of ESRD was 2.2% after 20 years and 7.0% after 30 years from the diabetes diagnosis. The relative risk of ESRD was 0.13 (95% CI 0.08-0.22) among patients diagnosed in 1995-2011 compared with those diagnosed in 1965-1979. Patients <5 years old at the time of diagnosis had the lowest risk of ESRD after diagnosis. With the cumulative risk of ESRD estimated from time of birth, the patients aged 5-9 years at diabetes diagnosis were at highest risk. CONCLUSIONS: The cumulative risk of ESRD has decreased markedly during the past five decades. This highlights the importance of modern treatment of diabetes and diabetic nephropathy.
Authors: Jessica L Harding; Meda E Pavkov; Dianna J Magliano; Jonathan E Shaw; Edward W Gregg Journal: Diabetologia Date: 2018-08-31 Impact factor: 10.122
Authors: Hongyan Liu; Vikas S Sridhar; Bruce A Perkins; Julio Rosenstock; David Z I Cherney Journal: Curr Diab Rep Date: 2022-05-28 Impact factor: 4.810
Authors: Marco Colombo; Stuart J McGurnaghan; Samira Bell; Finlay MacKenzie; Alan W Patrick; John R Petrie; John A McKnight; Sandra MacRury; Jamie Traynor; Wendy Metcalfe; Paul M McKeigue; Helen M Colhoun Journal: Diabetologia Date: 2019-12-05 Impact factor: 10.122
Authors: Jan Skupien; Adam M Smiles; Erkka Valo; Tarunveer S Ahluwalia; Beata Gyorgy; Niina Sandholm; Stephanie Croall; Maria Lajer; Kevin McDonnell; Carol Forsblom; Valma Harjutsalo; Michel Marre; Andrzej T Galecki; David-Alexandre Tregouet; Chun Yi Wu; Josyf C Mychaleckyj; Helen Nickerson; Marlon Pragnell; Stephen S Rich; Marcus G Pezzolesi; Samy Hadjadj; Peter Rossing; Per-Henrik Groop; Andrzej S Krolewski Journal: Diabetes Care Date: 2018-11-19 Impact factor: 19.112
Authors: Thomas Ebert; Sven-Christian Pawelzik; Anna Witasp; Samsul Arefin; Sam Hobson; Karolina Kublickiene; Paul G Shiels; Magnus Bäck; Peter Stenvinkel Journal: Toxins (Basel) Date: 2020-04-04 Impact factor: 4.546